+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Bevacizumab"

From
From
Ovarian Cancer - Pipeline Insight, 2024 - Product Thumbnail Image

Ovarian Cancer - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 450 Pages
  • Global
From
Global Retinoblastoma Treatment Market - Product Thumbnail Image

Global Retinoblastoma Treatment Market

  • Report
  • January 2024
  • 200 Pages
  • Global
From
Global Cancer Immunotherapy Market Analysis & Forecast to 2025 - Product Thumbnail Image

Global Cancer Immunotherapy Market Analysis & Forecast to 2025

  • Report
  • November 2020
  • 450 Pages
  • Global
From
Precision Cancer Therapeutics, 2022 - Product Thumbnail Image

Precision Cancer Therapeutics, 2022

  • Report
  • November 2022
  • 154 Pages
  • Global
From
From
From
From
From
From
From
From
From
From
From
Loading Indicator

Bevacizumab is a monoclonal antibody used in the treatment of various types of cancer. It is used in combination with other drugs to treat metastatic colorectal cancer, non-small cell lung cancer, glioblastoma, metastatic renal cell carcinoma, and metastatic breast cancer. Bevacizumab works by inhibiting the growth of new blood vessels, which can help slow the growth of tumors. It is administered intravenously and is typically given in combination with other chemotherapy drugs. Bevacizumab is a widely used drug in the oncology market, and is one of the most prescribed drugs for cancer treatment. It is used in combination with other drugs to treat a variety of cancers, and is often used in combination with chemotherapy. Bevacizumab has been shown to be effective in treating certain types of cancer, and is generally well tolerated. Some companies in the Bevacizumab market include Genentech, Roche, Pfizer, Merck, and Bristol-Myers Squibb. Show Less Read more